Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including CNS, pain and respiratory, has launched its drug product Copaxone® in the pre-filled autoinjector YpsoMate® from Ypsomed. Copaxone® is used for the treatment of patients with relapsing forms of multiple sclerosis (MS). The collaboration with Teva marks the second commercial market entry of Ypsomed’s autoinjector YpsoMate®.
Ypsomed is presenting at the PDA Interest Group Meeting in Venice, 18 March 2019. Dr. Andreas Schneider is presenting how to effectively upgrade self-injection device platforms into integrated cloud-connected systems.
We are thrilled to display our latest device-to-cloud solution YDS SmartServices at HIMSS19 in Orlando, 12-14 February at Philips booth No 2101. Our live demo will provide real-world insights into how YDS SmartServices enables secure device-to-cloud integration to simplify access to therapy-relevant data.
Ypsomed Delivery Systems is showcasing its complete range of self-injection devices including YpsoDose, the large volume wearable injector, at the upcoming Pharmapack Europe. The event will take place in Paris, France, on 6-7 February. Come and experience our custom products first hand at Paris Expo, Porte de Versailles, Hall 7.2. We look forward to meeting you at booth F74!
Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Hulio® and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Hulio® is a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. The drug is used in the treatment of various chronic autoimmune diseases.
Jakob Lange from Ypsomed will give you an overview of device options and talk about combination products and self-injection devices for biosimilars at the International Biosimilars Summit on November 29-30 in Berlin.
Burgdorf and Eindhoven (NL) – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, and Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based HealthSuite Digital Platform. The two companies agree to build a solution for Ypsomed’s new SmartServices™ based on Philips HealthSuite Digital Platform. The combination of Ypsomed connected self-medication devices with Philips’ HealthSuite Digital Platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services for enhanced patient outcomes.